<DOC>
	<DOCNO>NCT01211483</DOCNO>
	<brief_summary>This Phase 1b/2 study . In Phase 1b , subject know treatment receiving . Subjects receive Erlotinib + U3-1287 . The Phase 1b portion determine add U3-1287 Erlotinib safe subject advance non-small cell lung cancer fail prior treatment . In Phase 2 portion , subject blind treatment receive . Subjects receive either Erlotinib alone Erlotinib + U3-1287 . The Phase 2 portion determine add U3-1287 Erlotinib safe improve survival subject advance non-small cell lung cancer fail first treatment .</brief_summary>
	<brief_title>Study Erlotinib With Without Investigational Drug ( U3-1287 ) Subjects With Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically cytologically confirm stage IIIB IV NSCLC . Recurrent disease ( either response treatment subsequent relapse objective response ) progress first line therapy . Measurable disease . â‰¥ 18 year age . ECOG performance status 0 1 . Adequate organ bone marrow function . Agreement use effective contraception treatment least 6 month end treatment . Treatment anticancer therapy , antibody base therapy , retinoid therapy , hormonal therapy within 4 week study treatment . Left ventricular ejection fraction ( LVEF ) &lt; 45 % . Therapeutic radiation major surgery within 4 week study treatment palliative radiation therapy within 2 week study drug treatment . Previous use EGFRtargeted regimen , antiHER2 , antiHER3 , antiHER4 therapy . More 2 prior chemotherapy regimen NSCLC ( Phase 2 subject ) . Uncontrolled infection require IV antibiotic , antiviral , antifungal , know human immunodeficiency virus ( HIV ) infection , active hepatitis B C infection time screen . Clinically active brain metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Lung cancer</keyword>
</DOC>